160 related articles for article (PubMed ID: 20683061)
1. CCND1 and CDKN1B polymorphisms and risk of breast cancer.
Canbay E; Eraltan IY; Cercel A; Isbir T; Gazioglu E; Aydogan F; Cacina C; Cengiz A; Ferahman M; Zengin E; Unal H
Anticancer Res; 2010 Jul; 30(7):3093-8. PubMed ID: 20683061
[TBL] [Abstract][Full Text] [Related]
2. Association of cyclin D1 genotype with breast cancer risk and survival.
Shu XO; Moore DB; Cai Q; Cheng J; Wen W; Pierce L; Cai H; Gao YT; Zheng W
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):91-7. PubMed ID: 15668481
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer and cyclin D1 gene polymorphism in Turkish women.
Yaylim-Eraltan I; Ergen A; Görmüs U; Arikan S; Küçücük S; Sahin O; Yigit N; Yildiz Y; Isbir T
In Vivo; 2009; 23(5):767-72. PubMed ID: 19779113
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.
Naidu R; Yip CH; Taib NA
Neoplasma; 2008; 55(2):87-95. PubMed ID: 18237245
[TBL] [Abstract][Full Text] [Related]
5. The influence of cyclin D1 A870G polymorphism on colorectal cancer risk and prognosis in a Turkish population.
Yaylim-Eraltan I; Arikan S; Yildiz Y; Cacina C; Ergen HA; Tuna G; Görmüs U; Zeybek U; Isbir T
Anticancer Res; 2010 Jul; 30(7):2875-80. PubMed ID: 20683026
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
Gautschi O; Hugli B; Ziegler A; Bigosch C; Bowers NL; Ratschiller D; Jermann M; Stahel RA; Heighway J; Betticher DC
Lung Cancer; 2006 Mar; 51(3):303-11. PubMed ID: 16406195
[TBL] [Abstract][Full Text] [Related]
7. Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer.
Jain M; Kumar S; Lal P; Tiwari A; Ghoshal UC; Mittal B
Cancer Detect Prev; 2007; 31(3):225-32. PubMed ID: 17561354
[TBL] [Abstract][Full Text] [Related]
8. P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer.
Naidu R; Har YC; Taib NA
J Exp Clin Cancer Res; 2007 Mar; 26(1):133-40. PubMed ID: 17550142
[TBL] [Abstract][Full Text] [Related]
9. Association of cyclin D1 A870G polymorphism with two malignancies: acute lymphoblastic leukemia and breast cancer.
Bedewy AM; Mostafa MH; Saad AA; El-Maghraby SM; Bedewy MM; Hilal AM; Kandil LS
J BUON; 2013; 18(1):227-38. PubMed ID: 23613410
[TBL] [Abstract][Full Text] [Related]
10. MDR1 C3435T polymorphism in patients with breast cancer.
Turgut S; Yaren A; Kursunluoglu R; Turgut G
Arch Med Res; 2007 Jul; 38(5):539-44. PubMed ID: 17560460
[TBL] [Abstract][Full Text] [Related]
11. GG genotype of cyclin D1 G870A polymorphism is associated with non-cardiac gastric cancer in a high-risk region of China.
Jia A; Gong J; Li Y; Hao Z; Chang X; Dai F; Yu B
Scand J Gastroenterol; 2008; 43(11):1353-9. PubMed ID: 18609126
[TBL] [Abstract][Full Text] [Related]
12. CDKN1B V109G polymorphism frequency and prostate cancer risk in Taiwan.
Huang SP; Yu CC; Liu CC; Wu TT; Huang CH; Wu MT
Urol Int; 2008; 81(1):36-40. PubMed ID: 18645269
[TBL] [Abstract][Full Text] [Related]
13. Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1.
Yu CP; Yu JC; Sun CA; Tzao C; Ho JY; Yen AM
Breast Cancer Res Treat; 2008 Jan; 107(1):95-102. PubMed ID: 18043898
[TBL] [Abstract][Full Text] [Related]
14. Association between polymorphisms of the BRCA2 gene and clinical parameters in breast cancer.
Krupa R; Sliwinski T; Morawiec Z; Pawlowska E; Zadrozny M; Blasiak J
Exp Oncol; 2009 Dec; 31(4):250-1. PubMed ID: 20010525
[TBL] [Abstract][Full Text] [Related]
15. Impact of the cyclin D1 A870G polymorphism on susceptibility to sporadic colorectal cancer in Taiwan.
Huang WS; Tang R; Lin PY; Changchien CR; Chen JS; Chiang JM; Yeh CY; Wang JY; Hsieh LL
Dis Colon Rectum; 2006 May; 49(5):602-8. PubMed ID: 16552496
[TBL] [Abstract][Full Text] [Related]
16. Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers.
Grieu F; Malaney S; Ward R; Joseph D; Iacopetta B
Anticancer Res; 2003; 23(5b):4257-9. PubMed ID: 14666635
[TBL] [Abstract][Full Text] [Related]
17. CCND1 polymorphisms (A870G and C1722G) modulate its protein expression and survival in oral carcinoma.
Sathyan KM; Nalinakumari KR; Abraham T; Kannan S
Oral Oncol; 2008 Jul; 44(7):689-97. PubMed ID: 18061526
[TBL] [Abstract][Full Text] [Related]
18. Interaction of CCND1 genotype and smoking habit in Taiwan lung cancer patients.
Hsia TC; Liu CJ; Lin CH; Chang WS; Chu CC; Hang LW; Lee HZ; Lo WC; Bau DT
Anticancer Res; 2011 Oct; 31(10):3601-5. PubMed ID: 21965784
[TBL] [Abstract][Full Text] [Related]
19. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore.
Ceschi M; Sun CL; Van Den Berg D; Koh WP; Yu MC; Probst-Hensch N
Carcinogenesis; 2005 Aug; 26(8):1457-64. PubMed ID: 15845652
[TBL] [Abstract][Full Text] [Related]
20. Cyclin D1 polymorphism and the risk of endometrial cancer.
Kang S; Kim JW; Park NH; Song YS; Kang SB; Lee HP
Gynecol Oncol; 2005 May; 97(2):431-5. PubMed ID: 15863141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
